Menu
NuVision Biotherapies
NuVision has developed a unique way to process and preserve amnion which can be applied to the surface of the eye to promote healing of ‘front of eye’ disease and trauma.
Biotherapy
School of Medicine
Profile
Prior to NuVision, cryopreserved amnion had to be stored in specialist facilities. Delivery of the amnion had to be within thawing time before surgery which is a constraint for the NHS and meant the treatment could only be used for scheduled surgery.
NuVision’s first product, Omnigen® is a dry, sterile disc that does not require specialist storage conditions.
Omnigen® has further potential for use in human and veterinary treatments for conditions that feature chronic pain or inflammation, and flexible storage conditions potentially make it suitable for remote emergency treatment by military surgeons.
@NuVisBio on Twitter
NuVision wishes you all a very Merry Christmas and a Happy new year!
There are different surgical techniques for the application of amnion - Inlay Transplantation using a graft, Onlay Transplantation using a patch and the Combination Technique, which uses both. The technique used depends on factors such as the depth of the wound.
Champagne bottles can contain pressure as high as 90 pounds per square inch meaning a cork can leave a bottle at 50mph, which can cause eye damage. Omnigen provides amnion off the shelf, which can help aid ophthalmologists in emergency treatment: https://bit.ly/31NP5mM
It's estimated 4.5 million UK people have diabetes, with 10% developing foot ulcers (DFU). NuVision and Derby Clinical Trials Unit, are running a trial on using amniotic membrane to treat DFU, with data showing new treatment options. Learn more here: https://bit.ly/3niJmMP
Geert has worked for NuVision as our Regulatory and Scientific Affairs Manager since 2019. He believes NuVision’s biggest achievement so far has been developing an innovative procedure to deliver amnion in a convenient dehydrated form whilst protecting its natural properties.
Recurrent Corneal Erosion is a disorder resulting in ocular pain, blurred vision, tearing and photophobia. Small case study data shows sutureless AMT has been shown to reduce recurrent erosions after a 12-month review.
The "Innovations in amniotic membrane application in the management of ocular surface disease" webinar provided many useful insights such as this from Dr. Nick Kopsachilis. Watch the full recorded session here: https://bit.ly/3nLopM1
Dry eye disease affects up to 30% of over 50s. This is when the ocular surface is not appropriately moistened, which can lead to severely irritated eyes. Fortunately, amniotic membrane transplant has resulted in improvement in dry eye subjects when worn for around 5 days.
